Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NMPA Approval

Remimazolam Tosilate for Injection

Approval Number

国药准字H20217078

Company江苏恒瑞医药股份有限公司

Registration Date

September 10, 2021

Previous Approval Numbers

国药准字H20190034

Drug Information

Generic Name

注射用甲苯磺酸瑞马唑仑

Trade Name

瑞倍宁

Dosage Form

注射剂

Strength

25mg［按C₂₁H₁₉BrN₄O₂计］

Drug Type

化学药品

Registration Date

September 10, 2021

Company Information

Applicant Company

Company Name江苏恒瑞医药股份有限公司

Company Address

连云港经济技术开发区黄河路38号

Manufacturing Company

Company Name江苏恒瑞医药股份有限公司

Company Address

连云港经济技术开发区黄河路38号，连云港经济技术开发区临港产业区东晋路

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy

注射用甲苯磺酸瑞马唑仑 - NMPA 批准文号 | MedPath